Linfritz Research Institute — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$81,812	11
2024	Research	$106,550	12
2023	Research	$203,268	13
2022	Research	$131,004	16
2021	Research	$106,095	6
2020	Research	$179,081	33
2019	Research	$481,114	191

Breakdown

Who paid Research payments · program years 2019–2025

Eisai Inc. $1,026,047 266 payments
Teva Pharmaceuticals USA, Inc. $250,280 15 payments
GlaxoSmithKline, LLC. $12,597 1 payment

Studies the money was for Research payments · program years 2019–2025

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $628,729 58 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $397,318 208 payments
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma $250,280 15 payments
A Long Term, Randomised, Double Blind, Placebo-Controlled Study to Det $12,597 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.